Company intelligence / Profile preview

NeoPredics

Basel, Basel-Stadt, Switzerlandneopredics.com ↗

Ownership: Private
Development stage: Commercial

Overview

NeoPredics has developed clinically validated, AI-driven predictive analytics tools for maternal and neonatal care. Its flagship product, BiliPredics, forecasts bilirubin progression in newborns to enable early intervention for jaundice. The company completed a prospective multi-center observational study supporting its technology’s effectiveness.

Therapeutic areas: GastroenterologyWomen's Health
Modalities: Device (software-based clinical decision support)Predictive analytics platform
Industry: Digital Health Medical Devices

Partnerships

Dräger (integration of BiliPredics into Dräger’s neonatal care portfolio)

Beyond the preview

Go deeper on NeoPredics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoPredics.

Explore the full profile